Clinical Trial Update: Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for tislelizumab plus chemotherapy in resectable esophageal squamous cell carcinoma, followed by chemoradiotherapy or surgery; not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Chemotherapy (unspecified)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Esophagus Cancer | Phase 2 | Status: NOT_YET_RECRUITING